
|Videos|July 24, 2014
Early Treatment With Docetaxel for Metastatic Prostate Cancer
Author(s)Jyoti D. Patel, MD
Jyoti D. Patel, MD, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the early treatment of patients with metastatic prostate cancer.
Advertisement
Clinical Pearls
Jyoti D. Patel, MD, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the early treatment of patients with metastatic prostate cancer.
- Treatment with docetaxel early on improves survival for men who have early evidence of metastatic prostate cancer.
- Some patients have performance status that precludes treatment. As a result, they are never treated with the most active agents.
- This analysis will change practice: It will change who cares for patients early on and how they are treated.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















